Embedded Files
According to DelveInsight's evaluation, the worldwide Advanced Endometrial Cancer development landscape includes over 25 major pharmaceutical organizations actively pursuing more than 25 therapeutic candidates, encompassing Clinical Trial evaluations, Treatment approaches, Mechanisms of Action, Administration Routes, and Pipeline Advancements.
DelveInsight's "Advanced Endometrial Cancer Pipeline Insight, 2025" delivers extensive perspectives on the current clinical research landscape and expansion potential within the Advanced Endometrial Cancer therapeutic arena.
This Advanced Endometrial Cancer Pipeline analysis encompasses thorough commercial and clinical evaluations of investigational products spanning from preclinical stages through commercialization. The document features comprehensive drug descriptions, encompassing mechanisms of action, clinical research programs, regulatory submissions (where applicable), and developmental activities including technological innovations, partnerships, mergers and acquisitions, financial backing, regulatory designations, and additional product-specific information.
Key Highlights from the Advanced Endometrial Cancer Pipeline Analysis: https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
Pharmaceutical organizations worldwide are dedicating substantial efforts toward innovative Advanced Endometrial Cancer therapeutic development with notable achievements in recent years.
Organizations advancing Advanced Endometrial Cancer treatments include Incyte Corporation, Byondis, Hutchmed, Sanofi, 3D Medicines (Sichuan) Co. Novartis, AstraZeneca, Merck Sharp & Dohme, Huabo Biopharm Co, Iovance Biotherapeutics, Aadi Bioscience, Inc, Kartos Therapeutics, among others.
Investigational Advanced Endometrial Cancer treatments across various clinical development stages include Retifanlimab, Trastuzumab duocarmazine (SYD985), fruquintinib, XL147 (SAR245408), Envafolimab+Lenvatinib, BKM120, Olaparib, Lenvatinib, HB0025, Lifileucel, nab-sirolimus, Navtemadlin, and additional candidates anticipated to substantially influence the Advanced Endometrial Cancer marketplace in upcoming years.
During November 2025, The U.S. Food and Drug Administration (FDA) approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic tool to assist in identifying patients with microsatellite stable (MSS; indicating not MSI-high) endometrial carcinoma who could potentially benefit from treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, combined with LENVIMA® (lenvatinib), an orally administered multi-receptor tyrosine kinase inhibitor created by Eisai. This represents the initial FDA-authorized companion diagnostic from Promega.
During November 2025, Eisai unveiled new clinical research developments in gynecologic oncology at the International Gynecologic Cancer Society (IGCS) 2025 Annual Global Meeting in Cape Town, South Africa. A notable presentation features long-term follow-up outcomes from the Phase 3 Study 309/KEYNOTE-775 trial, which examined lenvatinib (LENVIMA®), Eisai's orally administered multi-targeted tyrosine kinase inhibitor, combined with pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy, versus physician's choice of treatment in patients with advanced endometrial carcinoma who had undergone at least one platinum-based therapy previously. The 5-year follow-up data was featured on November 5 during the Endometrial Cancer Master Session: New Approaches and Metastatic Setting (NCT03517449; Abstract #481). Previous long-term data were showcased at the ESMO Congress 2025, with additional insights shared at IGCS.
During June 2025, Genmab A/S (Nasdaq: GMAB) disclosed new data from cohort B2 of the Phase 1/2 RAINFOLTM-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeting ADC that administers a TOPO1 inhibitor. With a median on-study follow-up of 7.7 months, treatment with Rina-S at 100 mg/m2 every three weeks showed a confirmed objective response rate (ORR) of 50%, featuring two complete responses, in extensively pretreated patients with advanced endometrial cancer whose condition progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. The median duration of response remained unreached. These outcomes derive from the endometrial cancer monotherapy dose-expansion B2 cohort of the RAINFOL-01 trial, which investigates the safety and efficacy of Rina-S across solid tumors, and were showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Advanced Endometrial Cancer Disease Overview
Advanced endometrial cancer designates a phase of endometrial (uterine) cancer where the malignancy has extended beyond the uterus to adjacent tissues, lymph nodes, or remote organs including the ovaries, abdomen, lungs, or liver. At this phase, the cancer presents greater treatment challenges and frequently necessitates a combination of interventions, encompassing surgery, chemotherapy, radiation, hormonal therapy, or targeted treatments. Advanced endometrial cancer correlates with more aggressive disease characteristics and elevated recurrence risk, rendering early diagnosis and prompt management essential for improved outcomes.
Request a Free Sample PDF to learn more about Advanced Endometrial Cancer Pipeline Therapeutic Assessment: https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
Emerging Advanced Endometrial Cancer Compounds Across Various Clinical Development Phases Include:
Retifanlimab: Incyte Corporation
Trastuzumab duocarmazine (SYD985): Byondis
fruquintinib: Hutchmed
XL147 (SAR245408): Sanofi
Envafolimab+Lenvatinib: 3D Medicines (Sichuan) Co.
BKM120: Novartis
Olaparib: AstraZeneca
Lenvatinib: Merck Sharp & Dohme
HB0025: Huabo Biopharm Co
Lifileucel: Iovance Biotherapeutics
nab-sirolimus: Aadi Bioscience, Inc
Navtemadlin: Kartos Therapeutics
Advanced Endometrial Cancer Administration Routes
The Advanced Endometrial Cancer pipeline analysis presents therapeutic evaluation of developmental drugs by Administration Route. Products are classified under various routes including:
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Advanced Endometrial Cancer Molecular Classifications
Advanced Endometrial Cancer Products are organized under different Molecular types including:
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Advanced Endometrial Cancer Pipeline Therapeutic Evaluation
Advanced Endometrial Cancer Classification by Product Category
Advanced Endometrial Cancer By Development Phase and Product Category
Advanced Endometrial Cancer Classification by Administration Route
Advanced Endometrial Cancer By Development Phase and Administration Route
Advanced Endometrial Cancer Classification by Molecular Type
Advanced Endometrial Cancer by Development Phase and Molecular Type
DelveInsight's Advanced Endometrial Cancer Report encompasses approximately 25+ products across different clinical development phases including:
Late-phase products (Phase III)
Mid-phase products (Phase II)
Early-phase product (Phase I)
Preclinical and Discovery phase candidates
Discontinued & Inactive candidates
Administration Routes
Access additional details on Advanced Endometrial Cancer products in the comprehensive report. Download the Advanced Endometrial Cancer pipeline report to discover more about emerging Advanced Endometrial Cancer therapies: https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
Notable Organizations in the Advanced Endometrial Cancer Therapeutics Arena include:
Leading companies creating therapies for Advanced Endometrial Cancer include AstraZeneca, Daiichi Sankyo, Faeth Therapeutics, Hoffmann-La Roche, Merck, Karyopharm Therapeutics, Iovance Biotherapeutics, among others.
Advanced Endometrial Cancer Pipeline Evaluation:
The Advanced Endometrial Cancer pipeline document delivers insights into:
Comprehensive information about organizations creating therapies for Advanced Endometrial Cancer treatment with combined therapeutic candidates developed by individual companies.
Assessment of various therapeutic candidates organized into early-phase, mid-phase, and late-phase development for Advanced Endometrial Cancer Treatment.
Advanced Endometrial Cancer leading companies engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) initiatives.
Advanced Endometrial Cancer Drugs under investigation based on developmental phase, administration route, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classifications.
Comprehensive evaluation of partnerships (company-company collaborations and company-academia partnerships), licensing arrangements and financial details for future progression of the Advanced Endometrial Cancer marketplace.
The document is constructed utilizing data and intelligence gathered from the researcher's proprietary databases, company/university platforms, clinical trial registries, conferences, SEC documents, investor materials, and highlighted press announcements from company/university platforms and industry-focused third-party resources.
Download Sample PDF Report to explore more about Advanced Endometrial Cancer drugs and therapies: https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
Advanced Endometrial Cancer Pipeline Market Growth Factors
Escalating Prevalence of Endometrial Cancer, particularly among women with obesity, metabolic conditions, and advancing age.
Expanding Adoption of Precision Medicine, stimulating demand for targeted therapies and immunotherapies.
Progress in Genomic Profiling, facilitating identification of actionable mutations including MSI-H and MMR deficiency.
Robust R&D Funding by pharmaceutical organizations concentrating on innovative biologics, antibody-drug conjugates (ADCs), and combination therapies.
Regulatory Assistance, encompassing fast-track designations for promising therapies addressing unmet medical requirements.
Advanced Endometrial Cancer Pipeline Market Challenges
Elevated Clinical Trial Failure Rates, attributed to disease heterogeneity and intricate tumor biology.
Restricted Biomarker-Driven Therapies, as not all patients demonstrate actionable molecular targets.
Substantial Treatment Expenses, limiting access in low- and middle-income territories.
Adverse Reactions of Current Therapies, affecting patient compliance and long-term treatment adoption.
Delayed Patient Recruitment in clinical investigations, particularly for late-stage disease.
Regulatory Obstacles, encompassing stringent approval processes for novel therapies.
Competition from Established Treatments, which can constrain uptake of new drug candidates.
Scope of Advanced Endometrial Cancer Pipeline Drug Analysis
Geographic Coverage: Global
Key Advanced Endometrial Cancer Organizations: Incyte Corporation, Byondis, Hutchmed, Sanofi, 3D Medicines (Sichuan) Co. Novartis, AstraZeneca, Merck Sharp & Dohme, Huabo Biopharm Co, Iovance Biotherapeutics, Aadi Bioscience, Inc, Kartos Therapeutics, and others
Key Advanced Endometrial Cancer Treatments: Retifanlimab, Trastuzumab duocarmazine (SYD985), fruquintinib, XL147 (SAR245408), Envafolimab+Lenvatinib, BKM120, Olaparib, Lenvatinib, HB0025, Lifileucel, nab-sirolimus, Navtemadlin, and others
Advanced Endometrial Cancer Therapeutic Classification: Advanced Endometrial Cancer currently marketed and Advanced Endometrial Cancer emerging treatments
Advanced Endometrial Cancer Market Forces: Advanced Endometrial Cancer market growth factors and Advanced Endometrial Cancer market challenges
About DelveInsight
DelveInsight represents a premier Business Consultant and Market Research organization concentrated exclusively on life sciences. It supports Pharmaceutical companies by delivering comprehensive end-to-end solutions to enhance their performance. It additionally provides Healthcare Consulting Services, which contribute to market evaluation to accelerate business expansion and address challenges with a practical methodology.
Contact Information:
Kanishk
Page updated
Google Sites
Report abuse